Promising therapy candidates for liver fibrosis

Frontiers in Physiology

Volumn 7, Issue FEB, 2016, Pages

  Wang, Ping ^a,b,c   Koyama, Yukinori ^a,b,d   Liu, Xiao ^a,b   Xu, Jun ^a,b   Ma, Hsiao Yen ^a,b   Liang, Shuang ^a,b   Kim, In H ^a,b   Brenner, David A ^b   Kisseleva, Tatiana ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Cholangiocyte; Early phase clinical trial; Hepatocytes; Inflammation; Liver fibrosis; Myofibroblasts

Indexed keywords

1D 11; 2 (2 CHLOROPHENYL) 4 [3 (DIMETHYLAMINO)PHENYL] 5 METHYL 1H PYRAZOLO[4,3 C]PYRIDINE 3,6(2H,5H) DIONE; 3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; AB 0023; ALPHA TOCOPHEROL; ALPHAVBETA6 INTEGRIN ANTIBODY; ANTHOCYANIN; BETA LAPACHONE; BOC 1; CASPASE INHIBITOR; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; COV 08 0064; EMD 527040; EMRICASAN; ERITORAN; INTERLEUKIN 17 ANTIBODY; LADARIXIN; PAMREVLUMAB; PROTEIN ANTIBODY; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMTUZUMAB; SONIDEGIB; SURAMIN; TOLL LIKE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; VISMODEGIB; VX 166;

APOPTOSIS; CELL ACTIVATION; CELL PROLIFERATION; CHOLANGIOCYTE; DRUG TARGETING; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HEPATIC PROGENITOR CELL; HUMAN; INFLAMMATORY CELL; INTRACELLULAR SIGNALING; LIVER CELL; LIVER FIBROSIS; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOFIBROBLAST; NONHUMAN; PARENCHYMA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; STELLATE CELL;

EID: 84962803746     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2016.00047     Document Type: Short Survey

References (92)

1. Anstee, Q. M., Concas, D., Kudo, H., Levene, A., Pollard, J., Charlton, P., et al. (2010). Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 53, 542-550. doi: 10.1016/j.jhep.2010.03.016.
2. Aoyama, T., Paik, Y. H., Watanabe, S., Laleu, B., Gaggini, F., Fioraso-Cartier, L., et al. (2012). Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56, 2316-2327. doi: 10.1002/hep.25938.
3. Barreyro, F. J., Holod, S., Finocchietto, P. V., Camino, A. M., Aquino, J. B., Avagnina, A., et al. (2015). The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 35, 953-966. doi: 10.1111/liv.12570.
4. Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., et al. (2010). Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009-1017. doi: 10.1038/nm.2208.
5. Bettaieb, A., Jiang, J. X., Sasaki, Y., Chao, T. I., Kiss, Z., Chen, X., et al. (2015). Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of Steatohepatitis in mice. Gastroenterology 149, 468.e10-480.e10. doi: 10.1053/j.gastro.2015.04.009.
6. Bianchi, M. E. (2009). HMGB1 loves company. J. Leukoc. Biol. 86, 573-576. doi: 10.1189/jlb.1008585.
7. Brenner, D. A., Paik, Y. H., and Schnabl, B. (2015). Role of gut microbiota in liver disease. J. Clin. Gastroenterol. 49(Suppl. 1), S25-S27. doi: 10.1097/MCG.0000000000000391.
8. Canbay, A., Feldstein, A., Baskin-Bey, E., Bronk, S. F., and Gores, G. J. (2004). The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharmacol. Exp. Ther. 308, 1191-1196. doi: 10.1124/jpet.103.060129.
9. Cesaro, C., Tiso, A., Del Prete, A., Cariello, R., Tuccillo, C., Cotticelli, G., et al. (2011). Gut microbiota and probiotics in chronic liver diseases. Dig. Liver Dis. 43, 431-438. doi: 10.1016/j.dld.2010.10.015.
10. Chen, G., Zhang, L., Chen, L., Wang, H., Zhang, Y., and Bie, P. (2013). Role of integrin αvβ6 in the pathogenesis of ischemia-related biliary fibrosis after liver transplantation. Transplantation 95, 1092-1099. doi: 10.1097/TP.0b013e3182884866.
11. Choi, J. H., Choi, C. Y., Lee, K. J., Hwang, Y. P., Chung, Y. C., and Jeong, H. G. (2009). Hepatoprotective effects of an anthocyanin fraction from purple-fleshed sweet potato against acetaminophen-induced liver damage in mice. J. Med. Food. 12, 320-326. doi: 10.1089/jmf.2007.0691.
12. Christ, B., Brückner, S., and Winkler, S. (2015). The Therapeutic Promise of mesenchymal stem cells for liver restoration. Trends Mol. Med. 21, 673-686. doi: 10.1016/j.molmed.2015.09.004.
13. Chu, A. S., Diaz, R., Hui, J. J., Yanger, K., Zong, Y., Alpini, G., et al. (2011). Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 53, 1685-1695. doi: 10.1002/hep.24206.
14. Coombes, J. D., Swiderska-Syn, M., Dollé, L., Reid, D., Eksteen, B., Claridge, L., et al. (2015). Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. Gut 64, 1120-1131. doi: 10.1136/gutjnl-2013-306484.
15. de Gouville, A. C., Boullay, V., Krysa, G., Pilot, J., Brusq, J. M., Loriolle, F., et al. (2005). Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br. J. Pharmacol. 145, 166-177. doi: 10.1038/sj.bjp.0706172.
16. de Gouville, A. C., and Huet, S. (2006). Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect. 19, 85-90. doi: 10.1358/dnp.2006.19.2.977444.
17. De Minicis, S., and Brenner, D. A. (2007). NOX in liver fibrosis. Arch. Biochem. Biophys. 462, 266-272. doi: 10.1016/j.abb.2007.04.016.
18. De Minicis, S., Seki, E., Paik, Y. H., Osterreicher, C. H., Kodama, Y., Kluwe, J., et al. (2010). Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology 52, 1420-1430. doi: 10.1002/hep.23804.
19. di Bonzo, L. V., Ferrero, I., Cravanzola, C., Mareschi, K., Rustichell, D., Novo, E., et al. (2008). Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 57, 223-231. doi: 10.1136/gut.2006.111617.
20. Dixon, L. J., Berk, M., Thapaliya, S., Papouchado, B. G., and Feldstein, A. E. (2012). Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab. Invest. 92, 713-723. doi: 10.1038/labinvest.2012.45.
21. Donepudi, A. C., Aleksunes, L. M., Driscoll, M. V., Seeram, N. P., and Slitt, A. L. (2012). The traditional ayurvedic medicine, Eugenia jambolana (Jamun fruit), decreases liver inflammation, injury and fibrosis during cholestasis. Liver Int. 32, 560-573. doi: 10.1111/j.1478-3231.2011.02724.x.
22. Fan, X., Zhang, Q., Li, S., Lv, Y., Su, H., Jiang, H., et al. (2013). Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1. PLoS ONE 8:e82190. doi: 10.1371/journal.pone.0082190.
23. Fang, L., Huang, C., Meng, X., Wu, B., Ma, T., Liu, X., et al. (2014). TGF-β1-elevated TRPM7 channel regulates collagen expression in hepatic stellate cells via TGF-β1/Smad pathway. Toxicol. Appl. Pharmacol. 280, 335-344. doi: 10.1016/j.taap.2014.08.006.
24. Fang, L., Zhan, S., Huang, C., Cheng, X., Lv, X., Si, H., et al. (2013). TRPM7 channel regulates PDGF-BB-induced proliferation of hepatic stellate cells via PI3K and ERK pathways. Toxicol. Appl. Pharmacol. 272, 713-725. doi: 10.1016/j.taap.2013.08.009.
25. Federico, A., Dallio, M., Godos, J., Loguercio, C., and Salomone, F. (2015). Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl. Res. 167, 116-124. doi: 10.1016/j.trsl.2015.08.002.
26. Ge, X., Antoine, D. J., Lu, Y., Arriazu, E., Leung, T. M., Klepper, A. L., et al. (2014). High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J. Biol. Chem. 289, 22672-22691. doi: 10.1074/jbc.M114.552141.
27. Hao, C., Xie, Y., Peng, M., Ma, L., Zhou, Y., Zhang, Y., et al. (2014). Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo. Clin. Exp. Med. 14, 141-150. doi: 10.1007/s10238-013-0229-6.
28. Hartmann, P., Chen, P., Wang, H. J., Wang, L., McCole, D. F., Brandl, K., et al. (2013). Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 58, 108-119. doi: 10.1002/hep.26321.
29. Hauff, P., Gottwald, U., and Ocker, M. (2015). Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opin. Investig. Drugs 24, 309-327. doi: 10.1517/13543784.2015.997874.
30. Hirsova, P., Ibrahim, S. H., Bronk, S. F., Yagita, H., and Gores, G. J. (2013). Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS ONE 8:e70599. doi: 10.1371/journal.pone.0070599.
31. Hoque, R., Farooq, A., Malik, A., Trawick, B. N., Berberich, D. W., McClurg, J. P., et al. (2013). A novel small-molecule enantiomeric analogue of traditional (-)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage. J. Immunol. 190, 4297-4304. doi: 10.4049/jimmunol.1202184.
32. Hoque, R., Sohail, M. A., Salhanick, S., Malik, A. F., Ghani, A., Robson, S. C., et al. (2012). P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1171-G1179. doi: 10.1152/ajpgi.00352.2011.
33. Hou, Z., Qin, P., and Ren, G. (2010). Effect of anthocyanin-rich extract from black rice (Oryza sativa L. Japonica) on chronically alcohol-induced liver damage in rats. J Agric. Food Chem. 58, 3191-3196. doi: 10.1021/jf904407x.
34. Huang, C., Yu, W., Cui, H., Wang, Y., Zhang, L., Han, F., et al. (2014). P2X7 blockade attenuates mouse liver fibrosis. Mol. Med. Rep. 9, 57-62. doi: 10.3892/mmr.2013.1807.
35. Jiang, J. X., Chen, X., Serizawa, N., Szyndralewiez, C., Page, P., Schröder, K., et al. (2012). Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic. Biol. Med. 53, 289-296. doi: 10.1016/j.freeradbiomed.2012.05.007.
36. Jung, Y., Witek, R. P., Syn, W. K., Choi, S. S., Omenetti, A., Premont, R., et al. (2010). Signals from dying hepatocytes trigger growth of liver progenitors. Gut 59, 655-665. doi: 10.1136/gut.2009.204354.
37. Kim do, Y., Chung, S. I., Ro, S. W., Paik, Y. H., Lee, J. I., Jung, M. K., et al. (2013). Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis 18, 1481-1491. doi: 10.1007/s10495-013-0896-5.
38. Kisseleva, T., Uchinami, H., Feirt, N., Quintana-Bustamante, O., Segovia, J. C., Schwabe, R. F., et al. (2006). Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J. Hepatol. 45, 429-438. doi: 10.1016/j.jhep.2006.04.014.
39. Korff, S., Loughran, P., Cai, C., Lee, Y. S., Scott, M., and Billiar, T. R. (2013). Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma. J. Surg. Res. 184, e17-e25. doi: 10.1016/j.jss.2013.03.023.
40. Kubes, P., and Mehal, W. Z. (2012). Sterile inflammation in the liver. Gastroenterology 143, 1158-1172. doi: 10.1053/j.gastro.2012.09.008.
41. Lacouture, M. E., Morris, J. C., Lawrence, D. P., Tan, A. R., Olencki, T. E., Shapiro, G. I., et al. (2015). Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol. Immunother. 64, 437-446. doi: 10.1007/s00262-015-1653-0.
42. Li, C., Kong, Y., Wang, H., Wang, S., Yu, H., Liu, X., et al. (2009). Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J. Hepatol. 50, 1174-1183. doi: 10.1016/j.jhep.2009.01.028.
43. Li, C., Zheng, S., You, H., Liu, X., Lin, M., Yang, L., et al. (2011). Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J. Hepatol. 54, 1205-1213. doi: 10.1016/j.jhep.2010.08.028.
44. Lin, H., Xu, R., Zhang, Z., Chen, L., Shi, M., and Wang, F. S. (2011). Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cell Mol. Immunol. 8, 19-22. doi: 10.1038/cmi.2010.57.
45. Ling, H., Roux, E., Hempel, D., Tao, J., Smith, M., Lonning, S., et al. (2013). Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS ONE 8:e54499. doi: 10.1371/journal.pone.0054499.
46. Lipson, K. E., Wong, C., Teng, Y., and Spong, S. (2012). CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 5:S24. doi: 10.1186/1755-1536-5-S1-S24.
47. Machado, M. V., Michelotti, G. A., Pereira, T. D., Boursier, J., Kruger, L., Swiderska-Syn, M., et al. (2014). Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut 67, 1148-1157. doi: 10.1136/gutjnl-2014-307362.
48. Marques, P. E., Amaral, S. S., Pires, D. A., Nogueira, L. L., Soriani, F. M., Lima, B. H., et al. (2012). Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure. Hepatology 56, 1971-1882. doi: 10.1002/hep.25801.
49. McDonald, B., Pittman, K., Menezes, G. B., Hirota, S. A., Slaba, I., Waterhouse, C. C., et al. (2010). Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330, 362-366. doi: 10.1126/science.1195491.
50. McDonald, K. A., Huang, H., Tohme, S., Loughran, P., Ferrero, K., Billiar, T., et al. (2015). Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) Signaling. Mol. Med. 20, 639-648. doi: 10.2119/molmed.2014.00076.
51. Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., et al. (2013). Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823. doi: 10.1038/ncomms3823.
52. Meindl-Beinker, N. M., Matsuzaki, K., and Dooley, S. (2012). TGF-β signaling in onset and progression of hepatocellular carcinoma. Dig. Dis. 30, 514-523. doi: 10.1159/000341704.
53. Mejias, M., Garcia-Pras, E., Tiani, C., Miquel, R., Bosch, J., and Fernandez, M. (2009). Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49, 1245-1256. doi: 10.1002/hep.22758.
54. Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., et al. (2012). Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143, 765-776. doi: 10.1053/j.gastro.2012.05.049.
55. Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., et al. (2014). Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9:e90353. doi: 10.1371/journal.pone.0090353.
56. Neef, M., Ledermann, M., Saegesser, H., Schneider, V., Widmer, N., Decosterd, L. A., et al. (2006). Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J. Hepatol. 44, 167-175. doi: 10.1016/j.jhep.2005.06.015.
57. Nitta, T., Kim, J. S., Mohuczy, D., and Behrns, K. E. (2008). Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 48, 909-919. doi: 10.1002/hep.22397.
58. Omenetti, A., Syn, W. K., Jung, Y., Francis, H., Porrello, A., Witek, R. P., et al. (2009). Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology 50, 518-527. doi: 10.1002/hep.23019.
59. Omenetti, A., Yang, L., Li, Y. X., McCall, S. J., Jung, Y., Sicklick, J. K., et al. (2007). Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab. Invest. 87, 499-514. doi: 10.1038/labinvest.3700537.
60. Oo, Y. H., Banz, V., Kavanagh, D., Liaskou, E., Withers, D. R., Humphreys, E., et al. (2012). CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J. Hepatol 57, 1044-1051. doi: 10.1016/j.jhep.2012.07.008.
61. Oude Munnink, T. H., Arjaans, M. E., Timmer-Bosscha, H., Schröder, C. P., Hesselink, J. W., Vedelaar, S. R., et al. (2011). PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J. Nucl. Med. 52, 2001-2008. doi: 10.2967/jnumed.111.092809.
62. Paik, Y. H., Kim, J., Aoyama, T., De Minicis, S., Bataller, R., and Brenner, D. A. (2014). Role of NADPH oxidases in liver fibrosis. Antioxid. Redox Signal. 20, 2854-2872. doi: 10.1089/ars.2013.5619.
63. Philips, G. M., Chan, I. S., Swiderska, M., Schroder, V. T., Guy, C., Karaca, G. F., et al. (2011). Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS ONE 6:e23943. doi: 10.1371/journal.pone.0023943.
64. Pockros, P. J., Schiff, E. R., Shiffman, M. L., McHutchison, J. G., Gish, R. G., Afdhal, N. H., et al. (2007). Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46, 324-329. doi: 10.1002/hep.21664.
65. Popov, Y., Patsenker, E., Stickel, F., Zaks, J., Bhaskar, K. R., Niedobitek, G., et al. (2008). Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J. Hepatol. 48, 453-464. doi: 10.1016/j.jhep.2007.11.021.
66. Pratap, A., Panakanti, R., Yang, N., Eason, J. D., and Mahato, R. I. (2010). Inhibition of endogenous hedgehog signaling protects against acute liver injury after ischemia reperfusion. Pharm. Res. 27, 2492-2504. doi: 10.1007/s11095-010-0246-z.
67. Pratap, A., Panakanti, R., Yang, N., Lakshmi, R., Modanlou, K. A., Eason, J. D., et al. (2011). Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: hope for marginal livers. Mol. Pharm. 8, 958-968. doi: 10.1021/mp200115v.
68. Pratap, A., Singh, S., Mundra, V., Yang, N., Panakanti, R., Eason, J. D., et al. (2012). Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. J. Drug Target 20, 770-782. doi: 10.3109/1061186X.2012.719900.
69. Russo, F. P., Alison, M. R., Bigger, B. W., Amofah, E., Florou, A., Amin, F., et al. (2006). The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 130, 1807-1821. doi: 10.1053/j.gastro.2006.01.036.
70. Scholten, D., Osterreicher, C. H., Scholten, A., Iwaisako, K., Gu, G., Brenner, D. A., et al. (2010). Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 139, 987-998. doi: 10.1053/j.gastro.2010.05.005.
71. Scholten, D., Reichart, D., Paik, Y. H., Lindert, J., Bhattacharya, J., Glass, C. K., et al. (2011). Migration of fibrocytes in fibrogenic liver injury. Am. J. Pathol. 179, 189-198. doi: 10.1016/j.ajpath.2011.03.049.
72. Schuppan, D., and Kim, Y. O. (2013). Evolving therapies for liver fibrosis. J. Clin. Invest. 123, 1887-1901. doi: 10.1172/JCI66028.
73. Shen, H., Sheng, L., Chen, Z., Jiang, L., Su, H., Yin, L., et al. (2014). Mouse hepatocyte overexpression of NF-κB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis. Hepatology 60, 2065-2076. doi: 10.1002/hep.27348.
74. Shin, S., Park, J., Li, Y., Min, K. N., Kong, G., Hur, G. M., et al. (2014). β-Lapachone alleviates alcoholic fatty liver disease in rats. Cell. Signal. 26, 295-305. doi: 10.1016/j.cellsig.2013.11.020.
75. Syn, W. K., Jung, Y., Omenetti, A., Abdelmalek, M., Guy, C. D., Yang, L., et al. (2009). Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 137, 1478.e8-1488.e8. doi: 10.1053/j.gastro.2009.06.051.
76. Szondy, Z., Sarang, Z., Molnar, P., Nemeth, T., Piacentini, M., Mastroberardino, P. G., et al. (2003). Transglutaminase 2-/-mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc. Natl. Acad. Sci. U.S.A. 100, 7812-7817. doi: 10.1073/pnas.0832466100.
77. Tang, Y., Bian, Z., Zhao, L., Liu, Y., Liang, S., Wang, Q., et al. (2011). Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin. Exp. Immunol. 166, 281-290. doi: 10.1111/j.1365-2249.2011.04471.x.
78. Taura, K., Miura, K., Iwaisako, K., Osterreicher, C. H., Kodama, Y., Penz-Osterreicher, M., et al. (2010). Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51, 1027-1036. doi: 10.1002/hep.23368.
79. Tayel, A., Abd El Galil, K. H., Ebrahim, M. A., Ibrahim, A. S., El-Gayar, A. M., and Al-Gayyar, M. M. (2014). Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme. Eur. J. Pharmacol. 728, 151-160. doi: 10.1016/j.ejphar.2014.02.001.
80. Thapaliya, S., Wree, A., Povero, D., Inzaugarat, M. E., Berk, M., Dixon, L., et al. (2014). Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. Dig. Dis. Sci. 59, 1197-1206. doi: 10.1007/s10620-014-3167-6.
81. Trachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R., Peters, H., et al. (2011). A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243. doi: 10.1038/ki.2011.33.
82. Tugues, S., Fernandez-Varo, G., Muñoz-Luque, J., Ros, J., Arroyo, V., Rodés, J., et al. (2007). Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46, 1919-1926. doi: 10.1002/hep.21921.
83. Wang, B., Dolinski, B. M., Kikuchi, N., Leone, D. R., Peters, M. G., Weinreb, P. H., et al. (2007). Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 46, 1404-1412. doi: 10.1002/hep.21849.
84. Wang, L., Chen, S., and Xu, K. (2011). IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int. J. Mol. Med. 27, 385-392. doi: 10.3892/ijmm.2011.594.
85. Wang, Y., Chen, X., Cao, W., and Shi, Y. (2014). Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15, 1009-1016. doi: 10.1038/ni.3002.
86. Wells, R. G. (2014). The portal fibroblast: not just a poor man's stellate cell. Gastroenterology 147, 41-47. doi: 10.1053/j.gastro.2014.05.001.
87. Witek, R. P., Stone, W. C., Karaca, F. G., Syn, W. K., Pereira, T. A., Agboola, K. M., et al. (2009). Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50, 1421-1430. doi: 10.1002/hep.23167.
88. Ye, J. S., Su, X. S., Stoltz, J. F., de Isla, N., and Zhang, L. (2015). Signalling pathways involved in the process of mesenchymal stem cells differentiating into hepatocytes. Cell Prolif. 48, 157-165. doi: 10.1111/cpr.12165.
89. Yoshiji, H., Noguchi, R., Kuriyama, S., Ikenaka, Y., Yoshii, J., Yanase, K., et al. (2005). Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G907-G913. doi: 10.1152/ajpgi.00420.2004.
90. Zeisberg, M., Yang, C., Martino, M., Duncan, M. B., Rieder, F., Tanjore, H., et al. (2007). Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337-23347. doi: 10.1074/jbc.M700194200.
91. Zhang, X., Tan, Z., Wang, Y., Tang, J., Jiang, R., Hou, J., et al. (2015). PTPRO-associated hepatic stellate cell activation plays a critical role in liver fibrosis. Cell. Physiol. Biochem. 35, 885-898. doi: 10.1159/000369746.
92. Zhang, Y., Chen, L., Gao, W., Hou, X., Gu, Y., Gui, L., et al. (2012). IL-17 neutralization significantly ameliorates hepatic granulomatous inflammation and liver damage in Schistosoma japonicum infected mice. Eur. J. Immunol. 42, 1523-1535. doi: 10.1002/eji.201141933.